Literature DB >> 6767643

Hepatitis type A, B, and non-A non-B in fulminant hepatitis.

L R Mathiesen, P Skinoj, J O Nielsen, R H Purcell, D Wong, L Ranek.   

Abstract

Serological investigations for hepatitis B surface and e antigen, antibody to hepatitis B surface, core and e antigen and antibody to hepatitis A virus were carried out in 22 patients with fulminant hepatitis admitted to Medical Department A, Rigshospitalet, Copenhagen, in 1970-77. Nine patients had hepatitis type B and four type A. One patient had evidence of both type A and B infection, whereas the remaining eight patients showed no evidence of type A or B infection. Two of these had been treated with disulfiram and a drug aetiology could not be excluded, but in six patients no known cause of fulminant hepatitis could be determined and these patients were classified as having hepatitis type non-A non-B. The survival rate was not statistically different for patients having type A, B, or non-A non-B hepatitis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6767643      PMCID: PMC1419573          DOI: 10.1136/gut.21.1.72

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Transfusion-associated hepatitis not due to viral hepatitis type A or B.

Authors:  S M Feinstone; A Z Kapikian; R H Purcell; H J Alter; P V Holland
Journal:  N Engl J Med       Date:  1975-04-10       Impact factor: 91.245

2.  Charcoal haemoperfusion in the treatment of fulminant hepatic failure.

Authors:  B G Gazzard; M J Weston; I M Murray-Lyon; H Flax; C O Record; R Williams; B Portmann; P G Langley; E H Dunlop; P J Mellon; M B Ward
Journal:  Lancet       Date:  1974-06-29       Impact factor: 79.321

3.  Controlled trial of exchange-transfusion therapy in fulminant hepatitis.

Authors:  A G Redeker; H S Yamahiro
Journal:  Lancet       Date:  1973-01-06       Impact factor: 79.321

4.  Radioimmunoassay for the detection of the core of the Dane particle and antibody to it.

Authors:  R H Purcell; J L Gerin; J B Almeida; P V Holland
Journal:  Intervirology       Date:  1974       Impact factor: 1.763

5.  The fulminant hepatic failure surveillance study. Brief review of the effects of presumed etiology and age of survival.

Authors:  C Trey
Journal:  Can Med Assoc J       Date:  1972-02-26       Impact factor: 8.262

6.  Evidence for viral hepatitis other than type A or type B among persons in Costa Rica.

Authors:  V M Villarejos; K A Visoná; C A Eduarte; P J Provost; M R Hilleman
Journal:  N Engl J Med       Date:  1975-12-25       Impact factor: 91.245

7.  Purification of hepatitis A antigen from feces and detection of antigen and antibody by immune adherence hemagglutination.

Authors:  Y Moritsugu; J L Dienstag; J Valdesuso; D C Wong; J Wagner; J A Routenberg; R H Purcell
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

8.  Hepatitis B antigen (HBSAg) and/or antibodies (anti-HBS and anti-HBC) in fulminant hepatitis: pathogenic and prognostic significance.

Authors:  C G Trepo; D Robert; J Motin; D Trepo; M Sepetjian; A M Prince
Journal:  Gut       Date:  1976-01       Impact factor: 23.059

9.  Enhanced HBsAb production in pathogenesis of fulminant viral hepatitis type B.

Authors:  I L Woolf; N El Sheikh; H Cullens; W M Lee; A L Eddleston; R Williams; A J Zuckerman
Journal:  Br Med J       Date:  1976-09-18

10.  Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness.

Authors:  S M Feinstone; A Z Kapikian; R H Purceli
Journal:  Science       Date:  1973-12-07       Impact factor: 47.728

View more
  17 in total

Review 1.  Animal models of fulminant hepatic failure.

Authors:  J Terblanche; R Hickman
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

Review 2.  Parenterally acquired non-A non-B hepatitis ten years on: advances in diagnosis and therapy.

Authors:  M R Jacyna; H C Thomas
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

3.  Fulminant hepatic failure and artificial liver support.

Authors:  A E Gimson; R Ede; S Braude; R D Hughes; P J Langley; R Williams
Journal:  Gastroenterol Jpn       Date:  1982-04

Review 4.  Fulminant hepatitis.

Authors:  S Sinclair; A Wakefield; G Levy
Journal:  Springer Semin Immunopathol       Date:  1990

Review 5.  Prophylactic treatment regimens for the prevention of hepatitis A. Current concepts.

Authors:  B J Kendall; W G Cooksley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

6.  Etiological spectrum of viral hepatitis and prevalence of markers of hepatitis A and B virus infection in north India.

Authors:  B N Tandon; B M Gandhi; Y K Joshi
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

7.  Prospective assessment of incidence of fulminant hepatitis in post-transfusion hepatitis: a study of 504 cases.

Authors:  S Takano; M Omata; M Ohto; Y Satomura
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

8.  Computed tomography findings for predicting severe acute hepatitis with prolonged cholestasis.

Authors:  Sang Jung Park; Jin Dong Kim; Yeon Seok Seo; Beom Jin Park; Min Ju Kim; Soon Ho Um; Chang Ha Kim; Hyung Joon Yim; Soon Koo Baik; Jin Yong Jung; Bora Keum; Yoon Tae Jeen; Hong Sik Lee; Hoon Jai Chun; Chang Duck Kim; Ho Sang Ryu
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

9.  Treatment of fulminant viral hepatic failure with prostaglandin E. A preliminary report.

Authors:  S B Sinclair; G A Levy
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

10.  Clinical and histological features of a group of patients with sporadic non-A, non-B hepatitis.

Authors:  M Bamber; A K Murray; I V Weller; A Morelli; P J Scheuer; H C Thomas; S Sherlock
Journal:  J Clin Pathol       Date:  1981-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.